Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women

16. april 2015 oppdatert av: Population Council
This is a Phase 2, dose-finding, cross-over study for the purposes of evaluating the effect of a NES/E2 transdermal gel delivery on ovulation suppression in normal ovulating women.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Forventet)

18

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Santiago, Chile
        • Instituto Chileno de Medicina Reproductiva
      • Santo Domingo, Den dominikanske republikk
        • Profamilia
    • California
      • Los Angeles, California, Forente stater, 90033
        • Women's and Children's Hospital; LA County/USC Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 40 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Woman is between 18 and 40 years of age
  • Has intact uterus and ovaries
  • Has regular menstrual cycles of 25-35 days duration
  • Able to comply with the protocol, including frequent blood sampling, and lives within the catchment area of the clinic
  • Understands the study procedures and agrees to participate in the study by giving written informed consent
  • Able to use non-hormonal, double-barrier contraceptives (e.g. condoms and diaphragm) with every act of intercourse, or has been sterilized with tubal ligation, or only male partner has been sterilized with vasectomy
  • Progesterone >10 nmol/L in at least one sample in the lead-in cycle

Exclusion Criteria:

  • All contraindications to OC use including
  • Thrombophlebitis or thromboembolic disorders
  • Past history of deep vein thrombophlebitis or thromboembolic disorders
  • Past or current cerebrovascular or coronary artery disease
  • Known or suspected carcinoma of the breast
  • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
  • Undiagnosed abnormal genital bleeding
  • Cholestatic jaundice of pregnancy or jaundice with prior pill use
  • Hepatic adenomas or carcinomas
  • Woman has a history of headaches with focal neurological symptoms
  • Known or suspected pregnancy
  • Aged >35 and smoker
  • BMI >29
  • Positive urine pregnancy test at the screening or baseline visit
  • Desired pregnancy within the duration of the study
  • Known hypersensitivity to progestins
  • Known hypersensitivity to estrogen
  • Undiagnosed vaginal discharge or vaginal lesions or abnormalities
  • In accordance with the Bethesda system of classification Women with a current abnormal Pap smear suggestive of high-grade pre cancerous lesion(s), including HGSIL, are excluded
  • Women with LGSIL or ASCUS/high-risk HPV positive may participate if further evaluated with colposcopy and biopsy and no evidence of a lesion with a severity >CIN I is present and/or endocervical curettage is negative
  • Women with a biopsy finding of CIN I should have follow up for this finding per standard of care; women are excluded if treatment is indicated In accordance with other Pap class systems
  • Women with high grade dysplasia are excluded
  • Women with low grade dysplasia or CIN I interpretation on Pap smear may participate based on investigator discretion in accordance with local standard of care
  • Breastfeeding
  • Cancer (past history of any carcinoma or sarcoma)
  • History of a significant psychiatric disorder, including severe depression.
  • Chronic or acute liver or renal disease
  • Hypertension-- controlled by medication or defined by diastolic BP 85 mm Hg or systolic BP 135mm Hg after 15 minutes rest
  • Dermatitis, psoriasis or other severe skin disorder
  • Known or suspected alcoholism or drug abuse
  • Clinically significant abnormalities of laboratory safety tests
  • Chronic disease or history of illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject
  • Woman is participating or has participated in another clinical study (involving an investigational drug) within one month prior to enrollment.
  • Use of injectable contraceptives during the previous 3 months (e.g. cyclofem) or 9 months (e.g. DMPA)
  • Use of oral contraceptives within the past 1 month
  • Use of concomitant drugs that may interact with the study drugs

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: 1
0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
Aktiv komparator: 2
1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
Aktiv komparator: 3
1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Determine with ultrasound scan (USS) measures and serum progesterone (P) assessment the lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles
Tidsramme: Subjects will remain in the study for approximately 8 months
Subjects will remain in the study for approximately 8 months

Sekundære resultatmål

Resultatmål
Tidsramme
Determine with USS and E2 serum levels the dose that can suppress follicle growth and replace estradiol at the physiological early follicular phase level
Tidsramme: Subjects will remain in the study for approximately 8 months
Subjects will remain in the study for approximately 8 months
Evaluate the correlation of NES and E2 serum levels with the percentage of ovulation suppression
Tidsramme: Subjects will remain in the study for approximately 8 months
Subjects will remain in the study for approximately 8 months
Evaluate the safety and tolerability of the formulations
Tidsramme: Subjects will remain in the study for approximately 8 months
Subjects will remain in the study for approximately 8 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. november 2008

Primær fullføring (Faktiske)

1. januar 2014

Studiet fullført (Faktiske)

1. januar 2014

Datoer for studieregistrering

Først innsendt

21. november 2008

Først innsendt som oppfylte QC-kriteriene

21. november 2008

Først lagt ut (Anslag)

24. november 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

17. april 2015

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. april 2015

Sist bekreftet

1. april 2015

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • Population Council #427

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere